Gender and age based differences in risk of proarrhythmia by dofetilide: A computational model study

Gender and age based differences in risk of proarrhythmia by dofetilide: A computational model study

Bibliographic Details
Main Authors:	Gonzalez, R, Gomis−Tena, J, Corrias, A, Ferrero, J, Rodriguez, B, Saiz, J
Format:	Conference item
Published:	IEEE 2010

Similar Items

Sex and age related differences in drug induced QT prolongation by dofetilide under reduced repolarization reserve in simulated ventricular cells
by: Gonzalez, R, et al.
Published: (2010)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
by: Muhammad Erfan Uddin, et al.
Published: (2022-08-01)

Assessment of Dofetilide or Sotalol Tolerability in the Elderly
by: Nikitha Yagnala PharmD, et al.
Published: (2024-01-01)

Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy
by: Chris Chen, et al.
Published: (2023-07-01)

Transgenic Rabbit Models in Proarrhythmia Research
by: István Baczkó, et al.
Published: (2020-06-01)

Dofetilide induced torsade de pointes: Mechanism, risk factors and management strategies
by: Abhishek Jaiswal, et al.
Published: (2014-11-01)

Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
by: Sara Dutta, et al.
Published: (2017-08-01)

Applications of machine learning in decision analysis for dose management for dofetilide.
by: Andrew E Levy, et al.
Published: (2019-01-01)

Corrigendum: Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
by: Sara Dutta, et al.
Published: (2017-12-01)

General principles for the validation of proarrhythmia risk prediction models: an extension of the CiPA in silico strategy
by: Li, Z, et al.
Published: (2019)

Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction
by: Cristian Trovato, et al.
Published: (2022-10-01)

Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes
by: Daiju Yamazaki, et al.
Published: (2018-04-01)

Assessment of drug-induced proarrhythmias due to pilsicainide in patients with atrial tachyarrhythmias
by: Hideki Koike, MD, et al.
Published: (2016-12-01)

Aging Model for Analyzing Drug-Induced Proarrhythmia Risks Using Cardiomyocytes Differentiated from Progeria-Patient-Derived Induced Pluripotent Stem Cells
by: Neil Daily, et al.
Published: (2023-07-01)

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
by: Delaunois, A, et al.
Published: (2021)

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment
by: Kelly C. Chang, et al.
Published: (2017-11-01)

Right ventricular lead proarrhythmia: A novel intervention for an under-recognized phenomenon
by: Justin Hayase, MD, et al.
Published: (2018-02-01)

Acute inhibition of the Na +/Ca 2+ exchanger reduces proarrhythmia in an experimental model of chronic heart failure
by: Milberg, P, et al.
Published: (2012)

Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.
by: Milberg, P, et al.
Published: (2012)

The KCa2 Channel Inhibitor AP14145, But Not Dofetilide or Ondansetron, Provides Functional Atrial Selectivity in Guinea Pig Hearts
by: Jeppe Egedal Kirchhoff, et al.
Published: (2019-06-01)

Noninvasive assessment of dofetilide plasma concentration using a deep learning (neural network) analysis of the surface electrocardiogram: A proof of concept study.
by: Zachi I Attia, et al.
Published: (2018-01-01)

Quantitative Comparison of Effects of Dofetilide, Sotalol, Quinidine, and Verapamil between Human Ex vivo Trabeculae and In silico Ventricular Models Incorporating Inter-Individual Action Potential Variability
by: Britton, O, et al.
Published: (2017)

Torsadogenic potential of a novel remyelinating drug clemastine for multiple sclerosis assessed in the rabbit proarrhythmia model
by: Satoshi Kawakami, et al.
Published: (2020-11-01)

An Evaluation of the Impact of Oral Magnesium Lactate on the Corrected QT Interval of Patients Receiving Sotalol or Dofetilide to Prevent Atrial or Ventricular Tachyarrhythmia Recurrence
by: Brian F. McBride, et al.
Published: (2006-04-01)

Proarrhythmia assessment in treatment with hydroxychloroquine and azithromycin hospitalized elderly COVID-19 patients - our experience
by: Raffaele Costa, et al.
Published: (2021-06-01)

Computer model of the effects of pinacidil on ATP−sensitive potassium current
by: Trenor, B, et al.
Published: (1998)

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
by: Annie Delaunois, et al.
Published: (2021-05-01)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2023-05-01)

In vivo analysis of torsadogenic potential of an antipsychotic drug paliperidone using the acute atrioventricular block rabbit as a proarrhythmia model
by: Mihoko Hagiwara, et al.
Published: (2016-09-01)

Proarrhythmia in the p.Met207Val PITX2c-Linked Familial Atrial Fibrillation-Insights From Modeling
by: Jieyun Bai, et al.
Published: (2019-10-01)

The Effects of SEA0400 on Ca2+ Transient Amplitude and Proarrhythmia Depend on the Na+/Ca2+ Exchanger Expression Level in Murine Models
by: Nils Bögeholz, et al.
Published: (2017-09-01)

Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study
by: Annie Delaunois, et al.
Published: (2023-02-01)

Intravenous anti-influenza drug oseltamivir will not induce torsade de pointes: Evidences from proarrhythmia model and action-potential assay
by: Yuji Nakamura, et al.
Published: (2016-05-01)

Calculations of the binding free energies of the Comprehensive in vitro Proarrhythmia Assay (CiPA) reference drugs to cardiac ion channels
by: Tatsuki Negami, et al.
Published: (2023-04-01)

Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA)
by: Seung-Hyun Yoon, et al.
Published: (2023-08-01)

Deep Learning-Based Proarrhythmia Analysis Using Field Potentials Recorded From Human Pluripotent Stem Cells Derived Cardiomyocytes
by: Zeinab Golgooni, et al.
Published: (2019-01-01)

Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach
by: Zhihua Li, et al.
Published: (2019-06-01)

An Open-Circuit Indirect Calorimetry Head Hood System for Measuring Methane Emission and Energy Metabolism in Small Ruminants
by: Carlos Fernández, et al.
Published: (2019-06-01)

Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects
by: Ai Goto, et al.
Published: (2018-06-01)

Assessing Developmental Differences inMetacognitive Skills With Computer Logfiles: Gender by Age Interactions
by: Marcel V.J. Veenman, et al.
Published: (2014-04-01)